-

Amplitude Surgical - First Quarter 2024-25: Consolidated Sales of €21.8m, +7.5% at Constant Exchange Rates

  • Consolidated sales of €21.8m, up +7.5% at constant exchange rates
  • Sales up 4.5% in France
  • Strong international growth thanks to subsidiaries, with sales up +20.1% at constant exchange rates

VALENCE, France--(BUSINESS WIRE)--Regulatory News:

Amplitude Surgical (ISIN: FR0012789667, Mnemo: AMPLI, PEA-PME eligible), the French market leader in surgical technologies for lower limb orthopedics, announces its consolidated sales for the first quarter of the 2024-25 financial year.

Olivier Jallabert, Chief Executive Officer of Amplitude Surgical, comments: "In the first quarter of the 2024-25 financial year, Amplitude Surgical continued its good momentum as the previous year, posting growth of +7.5% at constant exchange rates compared with the first quarter of 2023-24. Sales growth was driven in particular by a +20.1% increase at constant exchange rates in sales by international subsidiaries, and by a continued good level of business in France, up +4.5%."

Q1 sales for fiscal year 2024-2025

Q1 2024-25 Sales

30/09/2024

30/09/2023

Change at
current exchange rates

Change at
constant exchange rates

In K€ - IFRS

Knee and hip activities

21,753

20,507

6.1%

7.5%

Total

21,753

20,507

6.1%

7.5%

In the first quarter (July-September 2024) of the 2024-25 financial year, Amplitude Surgical sales came to €21.8 million, up 6.1% and 7.5% at constant exchange rates.

Sales in France rose by 4.5%, while international distributors were down -4.1%, and the Group's international subsidiaries recorded an increase of 14.1% at current exchange rates and 20.1% at constant exchange rates.

Amplitude Surgical's direct sales (French market and international subsidiaries), which account for almost 93% of total Group sales, rose by +8.5% at constant exchange rates.

In France, the Group continued to grow as in the previous year. France accounted for around 67% of Group sales in the first quarter of the 2024-25 financial year.

International subsidiaries reported strong growth at constant exchange rates in Belgium, Australia and Brazil, while sales in Switzerland and Germany were down.

Next press release:
Half-year sales 1st 2024-25: Thursday, February 20, 2025, after market close.

About Amplitude Surgical

Founded in 1997 in Valence, France, Amplitude Surgical is a leading French player in the global market for surgical technologies for lower limb orthopedics. Amplitude Surgical develops and markets high-end products for orthopedic surgery, covering the main pathologies affecting the hip and knee. Working in close collaboration with surgeons, Amplitude Surgical develops numerous high value-added innovations to best meet the needs of patients, surgeons and care facilities. A leading player in France, Amplitude Surgical is expanding internationally through its subsidiaries and a network of agents and exclusive distributors in over 30 countries. As of June 30, 2024, Amplitude Surgical employed 428 people and generated sales of nearly 106.0 million euros.

Contacts

Amplitude Surgical
Dimitri Borchtch
Chief Financial Officer
finances@amplitude-surgical.com
04 75 41 87 41

NewCap
Investor Relations
Thomas Grojean
amplitude@newcap.eu
01 44 71 94 94

NewCap
Media Relations
Nicolas Merigeau
amplitude@newcap.eu
01 44 71 94 98

Amplitude Surgical

BOURSE:AMPLI

Release Versions

Contacts

Amplitude Surgical
Dimitri Borchtch
Chief Financial Officer
finances@amplitude-surgical.com
04 75 41 87 41

NewCap
Investor Relations
Thomas Grojean
amplitude@newcap.eu
01 44 71 94 94

NewCap
Media Relations
Nicolas Merigeau
amplitude@newcap.eu
01 44 71 94 98

More News From Amplitude Surgical

Amplitude Surgical SA: Results of the Simplified Tender Offer

VALENCE, France--(BUSINESS WIRE)--Regulatory News: Amplitude Surgical (ISIN: FR0012789667, Ticker: AMPLI, eligible for PEA-PME), the French leader in surgical technologies for lower limb orthopedics. On 10 October 2025, the French Autorité des Marchés Financiers (AMF) announced the results of the simplified tender offer initiated by Zydus MedTech (France) SAS on Amplitude Surgical SA shares, following the closing of the offer on 9 October 2025. At the end of the offer, Zydus MedTech (France) SA...

Zydus Announces Completion of the Acquisition of an 85.6% Stake in Amplitude Surgical and Upcoming Filing of a Simplified Tender Offer

AHMEDABAD, India & VALENCE, France--(BUSINESS WIRE)--Regulatory News: Zydus Lifesciences Limited1 (“Zydus”), on March 11, 2025, entered into agreements with PAI and two minority shareholders of Amplitude Surgical (Paris:AMPLI) to acquire blocks of shares representing in aggregate 85.6% of Amplitude Surgical’s share capital and voting rights2 at a price of €6.25 per share and a total consideration of €256.8mn (the “Block Acquisition”). As all conditions precedent to the completion have now been...

Amplitude Surgical – Suspension of Listing

VALENCE, France--(BUSINESS WIRE)--Regulatory News: Amplitude Surgical company has requested Euronext to suspend the listing of its shares (ISIN: FR0012789667, Ticker: AMPLI, eligible PEA-PME) on Euronext market with effect as from the publication of this press release and pending publication of a further press release. About Amplitude Surgical Founded in 1997 in Valence, Amplitude Surgical is a leading French player in the global market for surgical technologies for lower limb orthopedics. Ampl...
Back to Newsroom